• Mashup Score: 1

    Katie Robinson is a medical writer based in New York. In patients with early relapsed multiple myeloma (MM), the addition of the anti-CD38 antibody isatuximab (Isa) to carfilzomib-dexamethasone (Kd) maintained the improved progression-free survival (PFS) reported in interim results of the phase III IKEMA study, according to a longer-term analysis of the study published in Blood Cancer Journal. 1 “Isa-Kd is a very active regimen in patients with early relapsed MM, reporting a PFS of close to three years,

    Tweet Tweets with this article
    • In patients with early relapsed #multiplemyeloma #MM, the addition of the anti-CD38 antibody #isatuximab to #carfilzomibdexamethasone was found to maintain the improved PFS that was reported in interim results of the phase III IKEMA study https://t.co/sk622HhCOC